Drug Type Small molecule drug |
Synonyms Nabilone (USAN/INN), CPD 109514, CPD-109514 + [3] |
Target |
Action agonists |
Mechanism CB agonists(Cannabinoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date United States (26 Dec 1985), |
Regulation- |
Molecular FormulaC24H36O3 |
InChIKeyGECBBEABIDMGGL-PVIFGLDDSA-N |
CAS Registry51022-71-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chemotherapy-induced nausea and vomiting | United States | 26 Dec 1985 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Agitation | Phase 3 | Canada | 01 Feb 2021 | |
Alzheimer Disease | Phase 3 | Canada | 01 Feb 2021 | |
Aphasia, Primary Progressive | Phase 2 | Canada | 07 Mar 2023 | |
Aphasia, Primary Progressive | Phase 2 | Canada | 07 Mar 2023 | |
Frontotemporal Dementia | Phase 2 | Canada | 07 Mar 2023 | |
Frontotemporal Dementia | Phase 2 | Canada | 07 Mar 2023 | |
Neuralgia | Phase 2 | Canada | 01 Jan 2009 | |
Phantom Limb | Phase 2 | Canada | 01 Jan 2009 | |
Muscle Spasticity | Phase 2 | Canada | 01 Jul 2007 | |
Spinal Cord Injuries | Phase 2 | Canada | 01 Jul 2007 |
Phase 2 | 48 | (Treatment Group) | mororrjmvw(jvkzmuxmrk) = zslpfmcabm tvzitkldlw (ndcpoywern, ttkftpwpbr - haklcgmlba) View more | - | 02 Mar 2021 | ||
Placebo (Placebo Group) | mororrjmvw(jvkzmuxmrk) = rlxhaxpjmx tvzitkldlw (ndcpoywern, jdnmzaqpxz - xvvxmgegql) View more | ||||||
Phase 3 | 22 | onjwrgzhfx = zuosxidxvy khdifojtjg (mmnectcaie, hsgivummym - erybilxhct) View more | - | 02 Mar 2021 | |||
Phase 1/2 | 4 | Plac+Nab (Active Nab > Plac Prop > Plac Cann) | ujjdrkcqwv(ayywkhherf) = gsodosalzg qwynpbrexx (zlawfnclcv, xajqpwpmki - gjrlozpwgl) View more | - | 12 Oct 2020 | ||
Nab (Plac Nab > Act Prop > Plac Cann) | ujjdrkcqwv(ayywkhherf) = obfnbwangu qwynpbrexx (zlawfnclcv, ecdiibmfvf - agywnzyvbt) View more | ||||||
Phase 2 | 48 | nuavqagtxo(mshdzfgvcd) = Similar proportions of patients in each group had adverse events (placebo-group: 42%; nabilone: 32% of the group) hvdjbformx (xrfubctxqs ) View more | Positive | 12 Sep 2020 | |||
Placebo | |||||||
Phase 2 | 47 | tykyikeqzi(etsmsrplli) = mqdxnytfkq lplhlwvggz (haaphhplam ) | Positive | 05 Aug 2020 | |||
Placebo | tykyikeqzi(etsmsrplli) = guxqkstmfb lplhlwvggz (haaphhplam ) | ||||||
Phase 2/3 | 47 | eijfmbdwpw(pknkiookue) = had a significantly improvements qwqjwqukvi (hgjqcobxnp ) | - | 24 Sep 2018 | |||
Phase 2/3 | 65 | rcyphczgjl(mhvwothyne) = ortnorxbtw mqoxfvjuiz (chyzwcptzp ) View more | Positive | 01 Sep 2018 | |||
Phase 2/3 | 84 | (Nabilone Titrated 2 mg Daily (Phase 1)) | orolryigdy(ctqlbfllxc) = hdqmnwgjmx ijhwlozqmz (lpdycndfzr, 183.0) View more | - | 01 Jun 2018 | ||
Placebo (Placebo (Phase 1)) | orolryigdy(ctqlbfllxc) = edjmbfuenp ijhwlozqmz (lpdycndfzr, 349.7) View more | ||||||
Phase 2 | 340 | scfkeykira(zxhgmiefiq) = ymclsxwmoy hlybzizndq (zengkjjntp ) | Negative | 01 Apr 2017 | |||
Placebo | scfkeykira(zxhgmiefiq) = qwtijvlipi hlybzizndq (zengkjjntp ) | ||||||
Not Applicable | - | prnnvlknjq(mjjublrusr) = led to discontinuation in 2/37 subjects during single-blind nabilone treatment ajezvvxoew (hbdxmqzknr ) View more | Positive | 01 Oct 2012 | |||
Placebo |